Moleculin Biotech Inc. has announced that it received a notification from the Nasdaq Stock Market LLC regarding its non-compliance with the Nasdaq Listing Rule 5550(b)(1). This rule requires companies to maintain a minimum of $2.5 million in stockholders' equity. As of May 23, 2025, Moleculin Biotech does not meet this requirement, nor does it fulfill alternative criteria related to market value of listed securities or net income from continuing operations. While this notification does not immediately affect the company's listing status on the Nasdaq Capital Market, Moleculin Biotech has 45 days to submit a compliance plan. If accepted, the company could be granted an extension of up to 180 days to meet the necessary requirements. Failure to have the plan accepted could lead to an appeal process, though success is not guaranteed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.